ELAVL4-AS1

Across TCGA pan-cancer cohorts, ELAVL4-AS1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ELAVL4-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ELAVL4-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types ELAVL4-AS1 is over-expressed in tumor, although a few such as LIHC and COAD show the opposite, repressed pattern.

LIHC, COAD, and CHOL are the cancer types where ELAVL4-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ELAVL4-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	−0.803	.001	5	view →
COAD	Female	All	−0.042	.004	4	view →
CHOL	Female	All	−2.173	<.001	3	view →
HNSC	All	All	−0.024	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ELAVL4-AS1–LIHC

Open the LIHC breakdown →